| Left ventricular remodeling: pathophysiology and treatment. | |
| | |
MedLine Citation:
|
PMID: 14724719 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Left ventricular (LV) remodeling, which can result from myocardial damage or ventricular pressure or volume overload, has genomic, cellular, and interstitial components with associated changes in ventricular size, shape, wall thickness, and function. It is a process that is detectable and measurable clinically, generally progressive, and associated with adverse outcomes. However, it is amenable to intervention, prevention, or reversal. Following myocardial infarction (MI), LV remodeling is particularly likely in patients with transmural or anterior infarction and in those with failed reperfusion or LV failure. Infarct artery patency and neurohormonal blockade are key management considerations for prevention or reversal of LV remodeling. Combination treatment with angiotensin-converting enzyme inhibition and beta-blockade is of proven benefit following MI, improving LV remodeling and long-term outcomes. |
| | |
Authors:
|
Norman Sharpe |
Related Documents
:
|
16014439 - Cine mr imaging of myocardial contractile impairment in patients with hypertrophic card... 8721639 - Limiting lipid peroxidation in the nonischemic zone of infarcted rat hearts by indometh... 14732199 - Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate... 17661029 - Pre- and post-synaptic sympathetic function in human hibernating myocardium. 2971309 - Cardiac function in systemic hypertension before and after reversal of left ventricular... 18625659 - Prognosis of large-vessel giant cell arteritis. 10678449 - Dilated cardiomyopathy: changing pathophysiological concepts and mechanisms of dysfunct... 835359 - Right atrial monophasic action potential in patients with paroxysmal supraventricular t... 11480379 - Interventional therapy for acute myocardial infarction. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Heart failure monitor Volume: 4 ISSN: 1470-8590 ISO Abbreviation: Heart Fail Monit Publication Date: 2003 |
Date Detail:
|
Created Date: 2004-01-15 Completed Date: 2004-04-09 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 101140283 Medline TA: Heart Fail Monit Country: England |
Other Details:
|
Languages: eng Pagination: 55-61 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of Auckland, Auckland, New Zealand. n.sharpe@auckland.ac.nz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use* Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Collagen / therapeutic use Drug Therapy, Combination Humans Myocardial Infarction / drug therapy*, physiopathology* Nitroglycerin / therapeutic use Ventricular Remodeling / physiology* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 55-63-0/Nitroglycerin; 9007-34-5/Collagen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway diseas...
Next Document: Management of scoliosis.